APVO - Aptevo gains after disclosing additional remission data in leukemia trial

Aptevo Therapeutics (NASDAQ:APVO) traded higher in the morning hours Thursday after the clinical-stage biotech announced new remission data on four additional patients enrolled in its Phase 1b expansion trial for lead candidate APVO436 in acute myeloid leukemia (AML). According to early data from the cohort 1 of the trial, four out of 11 response-evaluable patients (36%) including three new patients were found to reach remission while on therapy. Notably, one new patient was found to be in complete remission increasing the number of patients with complete remission to two. The cohort 1 patients had received APVO436 in combination with standard chemotherapy drug cytarabine or the standard chemotherapy triple drug combination MEC. In the monotherapy arm of the trial, new data indicated that another patient has achieved bone marrow complete remission (MLFS). . "The observed data are very encouraging and show a positive trend in the trial, potentially establishing a path

For further details see:

Aptevo gains after disclosing additional remission data in leukemia trial